Alan S. Wayne

University of Southern California — United States

Medicine · Health Sciences

50h-index12.7kcitations339works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(96), CAR-T cell therapy research(80), Hematopoietic Stem Cell Transplantation(50), Acute Myeloid Leukemia Research(36), Toxin Mechanisms and Immunotoxins(30)

Publications338 total

Direct measurement is required for accurate assessment of body composition during therapy for acute lymphoblastic leukemia: A report from the T2020-003 IDEAL2 trial
Blood·2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Blood·2025· 8 citedOpen Access
Norovirus Infection at the NIH Clinical Center from 2010 to 2023: A Comparative Analysis of Acute vs. Chronic Norovirus Infection with a Focus on Inborn Errors of Immunity
Journal of Human Immunity·2025Open Access
Evaluation of clinical factors associated with discordant estimated glomerular filtration rate values determined from creatinine vs cystatin C
American Journal of Health-System Pharmacy·2025
Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL
Blood·2025· 6 citedOpen Access
Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial
Pediatric Blood & Cancer·2025Open Access
WU-CART-007 Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
Transplantation and Cellular Therapy·2025Open Access
WU-CART-007, an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
Transplantation and Cellular Therapy·2025
Supplementary Figures from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
2025Open Access
Supplementary Data 1 from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
2025Open Access
Data from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
2025Open Access
942: EVALUATION OF MELATONIN VERSUS RAMELTEON FOR DELIRIUM PREVENTION
Critical Care Medicine·2025
CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
Blood Cancer Discovery·2024· 10 citedOpen Access
WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001
Blood·2024
Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
Blood·2024Open Access
WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
Blood·2024· 1 cited
WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Blood·2024
Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL
Blood Advances·2024· 8 citedOpen Access
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial
2024· 15 citedOpen Access
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium
JNCI Journal of the National Cancer Institute·2024Open Access
page 1 of 17Next →

Frequent Co-authors

Ira Pastan(10), Maryalice Stetler‐Stevenson(8), Nirali N. Shah(8), Robert J. Kreitman(8), Stefania Pittaluga(5), Deepa Bhojwani(5), Terry J. Fry(4), Seth M. Steinberg(4), Constance M. Yuan(4), David J. FitzGerald(4), Crystal L. Mackall(4), Elaine S. Jaffe(4), Michael Bishop(4), Cindy Delbrook(3), Marianna Sabatino(3), Daniel J. Weisdorf(3), Wyndham H. Wilson(3), David F. Stroncek(3), Ambrose Jong(3), Muller Fabbri(3)